GLMD (Galmed Pharmaceuticals) Revenue: $0.00 Mil (TTM As of Dec. 2025)


GLMD Galmed Pharmaceuticals Ltd GLMD
27 GF Score
Price $0.57
! 2 Warning Signs
View Full Analysis

What is Galmed Pharmaceuticals Revenue?

Galmed Pharmaceuticals GLMD -11.95% 27 Revenue is $0.00 Mil as of Dec. 2025. GuruFocus rates GLMD with a GF Score™ of 27/100. The stock has 2 warning signs investors should review.

Galmed Pharmaceuticals's revenue for the three months ended in Dec. 2025 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00 Mil. Galmed Pharmaceuticals's Revenue per Share for the three months ended in Dec. 2025 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Galmed Pharmaceuticals  (NAS:GLMD) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Galmed Pharmaceuticals Revenue Related Terms


Galmed Pharmaceuticals Revenue Historical Data

* Premium members only.

The historical data trend for Galmed Pharmaceuticals's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Galmed Pharmaceuticals Revenue Chart

Galmed Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Galmed Pharmaceuticals Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

GLMD vs FBLG, SXTP, CELZ: Revenue Comparison

For the Biotechnology subindustry, Galmed Pharmaceuticals's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Galmed Pharmaceuticals Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Galmed Pharmaceuticals's Revenue distribution charts can be found below:

* The bar in red indicates where Galmed Pharmaceuticals's Revenue falls into.


GLMD
27GF Score
Galmed Pharmaceuticals Ltd GLMD
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Galmed Pharmaceuticals Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of $0.00 Mil mean?
Galmed Pharmaceuticals (GLMD) has a Revenue of $0.00 Mil as of Dec. 2025. Revenue is the total amount a company generates as sales through its operations. View historical data on Galmed Pharmaceuticals and its competitors.
Is Galmed Pharmaceuticals' Revenue too high?
Galmed Pharmaceuticals' current Revenue is $0.00 Mil. Overall, Galmed Pharmaceuticals has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Galmed Pharmaceuticals' Revenue compare to FBLG and SXTP?
Galmed Pharmaceuticals' Revenue of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Galmed Pharmaceuticals and its competitors. Galmed Pharmaceuticals's current Revenue is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galmed Pharmaceuticals stock overvalued right now?
Galmed Pharmaceuticals (GLMD) has a current Revenue of $0.00 Mil. The current Revenue is $0.00 Mil. Galmed Pharmaceuticals' overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Galmed Pharmaceuticals (GLMD), the current Revenue is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Galmed Pharmaceuticals Business Description

Address c/o Meitar Law Offices, 16 Abba Hillel Road, Ramat Gan, ISR, 5250608
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. The company focuses on the development of Aramchol for combination therapy for GI oncological indications. The company is actively pursuing opportunities in the biotech and medtech spaces to expand and diversify its product pipeline targeting GI, cardiometabolic indications and other product candidates.
27GF Score

Get the complete analysis for GLMD

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.57
Price